欧美疯狂xxxxxbbbbb,色就色综合,久久一本精品久久精品66

PPG 2025 H1 Performance PPG PPG reported a 2.54% drop in H1 2025 revenue to $7.879B and an 11.31% fall in net profit. Despite this, strong growth in aerospace, marine, and protective coatings boosted performance in key segments.
Sanofi 2025 q2 Performance Sanofi Sanofi reports q2 2025 revenue of $21.9B, with Dupixent sales reaching $8B. Strong growth in immunology, vaccines, and new product launches. U.S. leads regional sales. Strategic acquisitions continue.
Dow Chemical Q2 Financial Report Financial statements Dow Chemical reports a Q2 2025 loss of $801 million, with declines across all business segments. Global cost pressures, plant closures, and strategic shifts shape the company’s outlook amidst industry slowdown.
Honeywell 2025 Q2 Financial Report Financial statements Honeywell reports strong Q2 2025 results with $10.4B in sales, 8% YoY growth, and updated full-year guidance. Strategic spin-offs and $13.5B in acquisitions drive transformation and portfolio optimization.
WuXi AppTec Delivers Best Ever Q2 Performance Financial statements WuXi AppTec reports its strongest Q2 ever in 2025, with revenue and profit seeing double-digit growth. Backed by a robust CRDMO model, the company raises its full-year guidance amid strong global demand for innovative drug development services.
Roche Clinical Project Termination and TIGIT Abandonment Roche Roche terminates 7 clinical projects including all TIGIT antibody trials, updates 2025 H1 results with strong revenue growth and advances key therapies in oncology, hematology, neurology, immunology, and ophthalmology.
Roche 2025 H1 Financial Report Roche Roche reports 7% growth in H1 2025, with Phesgo up 55% and Polivy up 46%. China revenue rises 9%. Strong gains in hematology, immunology, and ophthalmology offset legacy drug declines.
Johnson & Johnson 2025 Q2 Earnings Report Financial statements Johnson & Johnson's Q2 2025 earnings report highlights strong growth across Innovative Medicine and MedTech, driven by oncology breakthroughs and cardiovascular innovation despite industry headwinds.
Johnson & Johnson 2025 H1 Performance Financial statements Johnson & Johnson reports $45.64B revenue in H1 2025, driven by oncology growth. Darzalex hits $6.8B, Carvykti surges toward $2B. Neuroscience and immunology portfolios evolve amid strategic acquisitions.
Novartis Q2 2025 Earnings Report Financial statements Novartis reported strong Q2 2025 results with double-digit revenue growth, key product successes, and promising R&D breakthroughs. The company's innovation and strategic focus position it for sustained long-term leadership.

< Pre 1 2 3 456 7 8...15 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a